The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

doi:10.1016/j.ajcnut.2023.04.017

科研成果详情

题名	The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
作者	Liu, Yupeng1; Ruan, Binye2; Jiang, Huinan2; Le, Siyu2; Liu, Yi 2; Ao, Xuemei2; Huang, Yufeng2; Shi, Xudong2; Xue, Ru2; Fu, Xiaoyi2; Wang, Shuran2
发表日期	2023-09
发表期刊	The American journal of clinical nutrition 影响因子和分区
语种	英语
原始文献类型	Meta-Analysis ; Systematic Review ; Journal Article ; Research Support, Non-U.S. Gov't
关键词	dose-response meta-analysis glucagon-like peptide-1 receptor agonists (GLP-1RAs) randomized controlled trials (RCTs) trial sequential analysis (TSA) weight loss
其他关键词	LIRAGLUTIDE 3.0 MG ; INTENSIVE BEHAVIORAL-THERAPY ; POLYCYSTIC-OVARY-SYNDROME ; LIFE-STYLE MODIFICATION ; BODY-MASS INDEX ; EXENATIDE ; WOMEN ; PLACEBO ; MANAGEMENT ; LEADS
摘要	Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the treatment of obesity., To assess the weight-loss effects of GLP-1RAs in the treatment of patients with overweight or obesity without diabetes., This is a systematic review with meta-analysis and trial sequential analysis. PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from their inception to January 1, 2022. Eligible trials report on outcomes including body weight (BW), body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), or total body fat (TBF). Mean differences (MDs) and standardized mean differences (SMDs) were summarized using random-effects models., {AbstractText=Forty-one trials involving 15,135 participants were included. Compared with controls, GLP-1RAs significantly reduced BW (MD -5.319 kg, 95% CI: -6.465, -4.174), BMI (MD -2.373 kg/m2, 95% CI: -2.821, -1.924), WC (MD -4.302 cm, CI:-5.185 to -3.419), WHR (MD -0.011, CI -0.015 to -0.007), but not TBF (MD -0.320%, CI -1.420 to -0.780). Trial sequential analysis (TSA) supported conclusive evidence of the effects of GLP-1RAs on BW, BMI, and WC for weight loss. GLP-1RAs had nonlinear dose-response relationships with weight loss. Extensive sensitivity analyses demonstrated the robustness of the results, though the GRADE certainty of the evidence ranged from high to very low. High to moderate GRADE certainty of evidence suggested semaglutide as the most effective GLP-1RA agent, with the best efficacy and low to moderate risk of adverse effects.}, The present study provides conclusive evidence for the effect of GLP-1RAs on weight loss in a nonlinear dose-response manner in patients with obesity or overweight without diabetes. In terms of changes in BW, BMI, and WC, there is firm evidence for the overall weight-loss effects of GLP-1RAs. Of the GLP-1RAs, semaglutide might be the most effective agent.
资助项目	Wenzhou Medical University [89219029]
出版者	ELSEVIER SCIENCE INC
ISSN	0002-9165
EISSN	1938-3207
卷号	118 期号:3 页码:614-626
DOI	10.1016/j.ajcnut.2023.04.017
页数	13
WOS类目	Nutrition & Dietetics
WOS研究方向	Nutrition & Dietetics
WOS记录号	WOS:001071962900001
收录类别	PUBMED ; SCIE ; SCOPUS
在线发表日期	2023-09
URL	查看原文
PubMed ID	37661106
SCOPUSEID	2-s2.0-85168728809
自科自定义期刊分类	T3(B)类
通讯作者地址	[Wang, Shuran]Department of Nutrition and Food Hygiene,School of Public Health and Management,Wenzhou Medical University,Wenzhou,China ; [Fu, Xiaoyi]Department of Nutrition and Food Hygiene,School of Public Health and Management,Wenzhou Medical University,Wenzhou,China
Scopus学科分类	Medicine (miscellaneous);Nutrition and Dietetics
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/182742
专题	公共卫生学院
通讯作者	Fu, Xiaoyi; Wang, Shuran
作者单位	1.Department of Epidemiology and Biostatistics,School of Public Health and Management,Wenzhou Medical University,Wenzhou,China; 2.Department of Nutrition and Food Hygiene,School of Public Health and Management,Wenzhou Medical University,Wenzhou,China
第一作者单位	公共卫生学院
通讯作者单位	公共卫生学院
第一作者的第一单位	公共卫生学院
推荐引用方式 GB/T 7714	Liu, Yupeng,Ruan, Binye,Jiang, Huinan,et al. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials[J]. The American journal of clinical nutrition,2023,118(3):614-626.
APA	Liu, Yupeng., Ruan, Binye., Jiang, Huinan., Le, Siyu., Liu, Yi., ... & Wang, Shuran. (2023). The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. The American journal of clinical nutrition, 118(3), 614-626.
MLA	Liu, Yupeng,et al."The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials".The American journal of clinical nutrition 118.3(2023):614-626.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
SCI文章202301.pdf（3918KB）	期刊论文	作者接受稿	开放获取	CC BY-NC-SA	浏览下载